Canada Issues Renewed Warning Over Chantix
Canadian health officials are reiterating their concerns over Pfizer Inc.'s smoking-cessation drug Chantix as they mull further strengthening the drug's labeling to address the risk of serious adverse psychiatric effects that...To view the full article, register now.
Already a subscriber? Click here to view full article